Performance of <sup>111</sup>In-labelled PSMA ligand in patients with nodal metastatic prostate cancer: correlation between tracer uptake and histopathology from lymphadenectomy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 30062606.
- Also identified by DOI 10.1007/s00259-018-4094-0.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Intraoperative identification of lymph node (LN) metastases (LNM) detected on preoperative PSMA PET/CT may be facilitated by PSMA radioguided surgery with the use of a gamma probe. We evaluated the uptake of <sup>111</sup>In-labelled PSMA ligand DKFZ-617 (referred to as <sup>111</sup>In-PSMA-617) in unaffected LN and LNM at the level of single LN. Six patients with prostate cancer (PCa) with suspicion of LNM on preoperative PSMA PET/CT underwent <sup>111</sup>In-PSMA-617-guided lymphadenectomy (LA; four salvage LA and two primary LA). <sup>111</sup>In-PSMA-617 (109 ± 5 MBq). was injected Intravenously 48 h prior to surgery Template LAs were performed in small subregions: common, external, obturator and internal iliac vessels, and presacral and retroperitoneal subregions (n = 4). Samples from each subregion were isolated aiming at the level of single LN. Uptake was measured ex situ using a germanium detector. Receiver operating characteristic (ROC) analysis was performed based on <sup>111</sup>In-PSMA-617 uptake expressed as standardized uptake values normalized to lean body mass (SUL). Overall 310 LN (mean 52 ± 19.7) were removed from 74 subregions (mean 12 ± 3.7). Of the 310 LN, 35 turned out to be LNM on histopathology. Separation of the samples from all subregions resulted in 318 single specimens: 182 PCa-negative LN samples with 275 LN, 35 single LNM samples, 3 non-nodal PCa tissue samples and 98 fibrofatty tissue samples. The median SULs of nonaffected LN (0.16) and affected LN (13.2) were significantly different (p < 0.0001). Based on 38 tumour-containing and 182 tumour-free specimens, ROC analysis revealed an area under the curve of 0.976 (95% CI 0.95-1.00, p < 0.0001). Using a SUL cut-off value of 1.136, sensitivity, specificity, positive predictive value, negative predictive value and accuracy in discriminating affected from nonaffected LN were 92.1% (35/38), 98.9% (180/182), 94.6% (35/37), 98.4% (180/183) and 97.7% (215/220), respectively. Ex situ analysis at the level of single LN showed that <sup>111</sup>In-PSMA-617 had excellent ability to discriminate between affected and nonaffected LN in our patients with PCa. This tracer characteristic is a prerequisite for in vivo real-time measurements during surgery.
Medical subject headings
- Dipeptides
- Heterocyclic Compounds, 1-Ring
- Indium Radioisotopes
- Lymph Node Excision
- Prostatic Neoplasms